These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12191609)

  • 1. Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis.
    Gould C; Wong CF
    Pharmacol Ther; 2002; 93(2-3):169-78. PubMed ID: 12191609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational analysis of PKA-balanol interactions.
    Wong CF; Hünenberger PH; Akamine P; Narayana N; Diller T; McCammon JA; Taylor S; Xuong NH
    J Med Chem; 2001 May; 44(10):1530-9. PubMed ID: 11334563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of charge states of balanol analogues acting as ATP-competitive inhibitors in kinases.
    Hardianto A; Yusuf M; Liu F; Ranganathan S
    BMC Bioinformatics; 2017 Dec; 18(Suppl 16):572. PubMed ID: 29297286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.
    Koide K; Bunnage ME; Gomez Paloma L; Kanter JR; Taylor SS; Brunton LL; Nicolaou KC
    Chem Biol; 1995 Sep; 2(9):601-8. PubMed ID: 9383464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Protein kinase inhibitor balanol: structure-activity relationships and structure-based computational studies.
    Pande V; Ramos MJ; Gago F
    Anticancer Agents Med Chem; 2008 Aug; 8(6):638-45. PubMed ID: 18690827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential and selective inhibition of protein kinase A and protein kinase C in intact cells by balanol congeners.
    Gustafsson AB; Brunton LL
    Mol Pharmacol; 1999 Aug; 56(2):377-82. PubMed ID: 10419557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily.
    Setyawan J; Koide K; Diller TC; Bunnage ME; Taylor SS; Nicolaou KC; Brunton LL
    Mol Pharmacol; 1999 Aug; 56(2):370-6. PubMed ID: 10419556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3',5'-adenosine monophosphate-dependent protein kinase catalytic subunit.
    Akamine P; Madhusudan ; Brunton LL; Ou HD; Canaves JM; Xuong NH; Taylor SS
    Biochemistry; 2004 Jan; 43(1):85-96. PubMed ID: 14705934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking of balanol to dynamics snapshots of protein kinase A.
    Wong CF; Kua J; Zhang Y; Straatsma TP; McCammon JA
    Proteins; 2005 Dec; 61(4):850-8. PubMed ID: 16245317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of ligand binding to cAMP-dependent protein kinase.
    Hünenberger PH; Helms V; Narayana N; Taylor SS; McCammon JA
    Biochemistry; 1999 Feb; 38(8):2358-66. PubMed ID: 10029529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse dynamics features of novel protein kinase C (PKC) isozymes determine the selectivity of a fluorinated balanol analogue for PKCε.
    Hardianto A; Khanna V; Liu F; Ranganathan S
    BMC Bioinformatics; 2019 Feb; 19(Suppl 13):342. PubMed ID: 30717648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase.
    Narayana N; Diller TC; Koide K; Bunnage ME; Nicolaou KC; Brunton LL; Xuong NH; Ten Eyck LF; Taylor SS
    Biochemistry; 1999 Feb; 38(8):2367-76. PubMed ID: 10029530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
    Sims PA; Wong CF; McCammon JA
    J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Dynamics Pinpoint the Global Fluorine Effect in Balanoid Binding to PKCε and PKA.
    Hardianto A; Liu F; Ranganathan S
    J Chem Inf Model; 2018 Feb; 58(2):511-519. PubMed ID: 29341608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncoupling Catalytic and Binding Functions in the Cyclic AMP-Dependent Protein Kinase A.
    Kim J; Li G; Walters MA; Taylor SS; Veglia G
    Structure; 2016 Mar; 24(3):353-63. PubMed ID: 26833386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.
    Foloppe N; Fisher LM; Francis G; Howes R; Kierstan P; Potter A
    Bioorg Med Chem; 2006 Mar; 14(6):1792-804. PubMed ID: 16289938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design and evaluation of new lead compound structures for selective betaARK1 inhibitors.
    Iino M; Furugori T; Mori T; Moriyama S; Fukuzawa A; Shibano T
    J Med Chem; 2002 May; 45(11):2150-9. PubMed ID: 12014953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.
    Kassack MU; Högger P; Gschwend DA; Kameyama K; Haga T; Graul RC; Sadée W
    AAPS PharmSci; 2000; 2(1):E2. PubMed ID: 11741218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.